Search

Search Constraints

You searched for: Author/Creator Basu, Supratik

Search Results

1. COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma. (2nd August 2021)

2. COVID‐19 in haematology patients: a multicentre West Midlands clinical outcomes analysis on behalf of the West Midlands Research Consortium. (5th November 2020)

3. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Issue 11 (November 2021)

4. DPACE‐based chemotherapy in the era of myeloma novel agents: A UK multicentre study. (21st April 2020)

5. Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset. Issue 6 (26th June 2022)

6. Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study. Issue 11 (25th August 2012)

7. Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK‐wide real‐world cohort of relapsed myeloma patients. (31st January 2023)

9. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Issue 8 (2nd July 2020)

10. Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response. (17th February 2022)